Ascendis provides update on achondroplasia programmes
Ascendis Pharma has provided updates across its achondroplasia programme, including data from the COACH and ApproaCH trials.
Combination therapy update
The company announced that treatment with the combination of once-weekly TransCon CNP and once-weekly TransCon hGH has continued to demonstrate durable growth in children with achondroplasia, with a mean annualised growth velocity (AGV) meeting or exceeding the 97th percentile of children of average stature, without compromising safety or tolerability.
Consistent with Week 26 and Week 52 results, mean AGV for children treated with combination therapy through Week 78 in the Phase II COACH trial remained at or above the 97th percentile AGV of children of average stature, with changes over time following age-related growth patterns, and sustained increases in ACH height Z-score, indicating a tripling of efficacy compared to TransCon CNP monotherapy.
Children treated with combination therapy demonstrated continued improvements in body proportionality through Week 78, aligning with the increase in linear growth.
The combination therapy was generally well-tolerated, with a low incidence of injection site reactions and generally mild treatment-emergent adverse events (TEAEs).
To date, 100% of the 21 enrolled children completed 78 weeks of treatment and remain on therapy in the COACH Trial.
Monotherapy update
Ascendis also announced that treatment with once-weekly TransCon CNP monotherapy has demonstrated durable improvements in height, as well as benefits beyond height, and a safety and tolerability profile similar to placebo.
Week 104 data from the pivotal ApproaCH Trial of TransCon CNP at 100µg/kg once-weekly in children with achondroplasia aged 2 to 11 years demonstrated:
- Durable improvements in height as measured by AGV and height Z-scores over 104 weeks for those randomised to TransCon CNP, and significant improvement for those switching from placebo to TransCon CNP at Week 52.
- Benefits beyond height, including improvements in lower limb alignment and body proportionality, as demonstrated by improved tibial-femoral angle and upper-to-lower body segment ratio.
To date, 96% of the 140 children enrolled in the AttaCH long-term open-label extension trial remain on TransCon CNP monotherapy, with up to nearly six years of treatment, or are in the ongoing COACH combination therapy trial.
The AttaCH trial, following children to near-final adult height, continues to enrol children who complete TransCon CNP monotherapy trials (ACcomplisH, ApproaCH, teACH, and reACHin).
In the European Union, a decision is anticipated in the fourth quarter of 2026 for the Marketing Authorisation Application for TransCon CNP as a monotherapy.
“I am excited to see compelling long-term efficacy, safety, and tolerability data for TransCon CNP monotherapy,” said Carlos Bacino, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital.
“TransCon CNP has demonstrated positive effects compared to placebo on multiple aspects of skeletal growth, including statistically significant improvements in height and lower-limb alignment, with growing long-term data highlighting its unprecedented efficacy when used in combination with TransCon hGH. That and its once-weekly administration and low rate of injection site reactions mark it as an important potential new treatment option for children with achondroplasia.”
